Ads
related to: monoclonal antibody treatment prostate cancer bone metastases survival- Patient Story Videos
Watch Real Stories Of Patients
Who Have Battled Prostate Cancer.
- Learn About Advanced PC
Understand The Symptoms, Diagnosis
And Find Helpful Resources.
- Cancer Progression
Understand The Different Kinds Of
Prostate Cancer & Its Progression.
- Support Your Loved Ones
Explore Resources And Get Guidance
On How To Care For Someone With PC.
- Patient Story Videos
prostate.popado.net has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [21] [22] The most common side effects are joint and muscle pain in the arms or legs. [23]
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The anti-RANKL antibody, denosumab, is also approved for use in cancer settings, and in those indications, it is branded as Xgeva. In both prostate and breast cancer, denosumab has been shown to reduce cancer treatment–induced bone loss. [21]
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
Ipilimumab, in combination with nivolumab, is indicated for the treatment of adults and adolescents twelve years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Ads
related to: monoclonal antibody treatment prostate cancer bone metastases survivalprostate.popado.net has been visited by 10K+ users in the past month